Cara Therapeutics appoints Ryan Maynard as CFO, effective Sept 12, 2022

Tvardi Therapeutics, Inc.

Ryan Maynard appointed CFO effective September 12, 2022; principal financial and accounting officer.
Compensation: $460,000 base salary, 40% target bonus, 225,000 share option grant vesting over 4 years.
Maynard previously CFO of LetsGetChecked and Rigel Pharmaceuticals (10 years as CFO at Rigel).
Appointment aligns with ongoing launch of KORSUVA injection for chronic pruritus.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ryan Maynard

Chief Financial Officer

TVRD · Tvardi Therapeutics, Inc.

Effective: 2022-09-12
Filed: September 12, 2022, 7:59 PM ET

announced the appointment of Ryan Maynard to serve as Chief Financial Officer of the Company, effective September 12, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ryan Maynard was appointed as Chief Financial Officer at Tvardi Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

announced the appointment of Ryan Maynard to serve as Chief Financial Officer of the Company, effective September 12, 2022.

View on SEC.gov

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-099017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.